By a News Reporter-Staff News Editor at Biotech Week -- SynGen Inc., a company focused on the development and commercialization of instrument systems that harvest stem and progenitor cells from umbilical cord blood, bone marrow, peripheral blood, and cell culture, announced that Dr. William Gerber has been appointed CEO to replace co-founder and lead inventor Philip Coelho (see also SynGen Inc.).
Mr. Coelho, who will become the Chief Technical Officer (CTO) of SynGen, noted "Bud Barry, my business partner and co-founder, and I are gratified that Dr. Gerber has agreed to lead this company during this next critical phase of our development. Bill's experience includes nine years as an Investment Partner with Bay City Capital and nearly twenty years as a biotech executive focused on technology development and commercialization. I have worked with Bill extensively over the last two years and he has the energy, skills, and temperament needed to lead the company as we launch our advanced cell processing products."
Dr. Gerber, who previously served as Executive Chairman of the Board, said "I am very excited about the potential of the company's products to advance the field of regenerative medicine. Phil is a recognized innovator in cord blood processing, having developed the AXP and BioArchive Systems at Thermogenesis. The SynGenX line of products offers improved cell recovery, purity and viability to cord blood banks, and to the broader research, clinical and cell processing markets. We are already in discussions with potential strategic partners to assure that our products are made available to customers worldwide."
Keywords for this news article include: SynGen Inc.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC